- Home
- FMY vs AADI Comparison
FMY vs AADI Comparison
Compare FMY & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- AADI
- Stock Information
- Founded
- FMY 2005
- AADI 2011
- Country
- FMY United States
- AADI United States
- Employees
- FMY N/A
- AADI N/A
- Industry
- FMY Finance/Investors Services
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- AADI Health Care
- Exchange
- FMY Nasdaq
- AADI Nasdaq
- Market Cap
- FMY 50.9M
- AADI 59.4M
- IPO Year
- FMY N/A
- AADI N/A
- Fundamental
- Price
- FMY $12.00
- AADI $2.29
- Analyst Decision
- FMY
- AADI Hold
- Analyst Count
- FMY 0
- AADI 3
- Target Price
- FMY N/A
- AADI $1.75
- AVG Volume (30 Days)
- FMY 10.1K
- AADI 108.5K
- Earning Date
- FMY 01-01-0001
- AADI 11-06-2024
- Dividend Yield
- FMY 6.98%
- AADI N/A
- EPS Growth
- FMY N/A
- AADI N/A
- EPS
- FMY N/A
- AADI N/A
- Revenue
- FMY N/A
- AADI $25,070,000.00
- Revenue This Year
- FMY N/A
- AADI $9.39
- Revenue Next Year
- FMY N/A
- AADI $6.15
- P/E Ratio
- FMY N/A
- AADI N/A
- Revenue Growth
- FMY N/A
- AADI 7.80
- 52 Week Low
- FMY $10.71
- AADI $1.21
- 52 Week High
- FMY $12.17
- AADI $2.63
- Technical
- Relative Strength Index (RSI)
- FMY 45.22
- AADI 48.83
- Support Level
- FMY $11.97
- AADI $2.25
- Resistance Level
- FMY $12.18
- AADI $2.45
- Average True Range (ATR)
- FMY 0.16
- AADI 0.12
- MACD
- FMY -0.01
- AADI -0.02
- Stochastic Oscillator
- FMY 6.00
- AADI 10.64
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.